Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 27345636

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2016 Aug
First author
Sehn LH

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Aug;17(8):1023-1025. doi: 10.1016/S1470-2045(16)30157-7.
    note
    Source null
    related pmid
    27345637
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2016 Aug;13(8):466. doi: 10.1038/nrclinonc.2016.112.
    note
    Source null
    related pmid
    27402577
    relationship
    Comment in

Authors and identifiers

  1. name
    Sehn LH
    type
    Author
  2. name
    Chua N
    type
    Author
  3. name
    Mayer J
    type
    Author
  4. name
    Dueck G
    type
    Author
  5. name
    Trněný M
    type
    Author
  6. name
    Bouabdallah K
    type
    Author
  7. name
    Fowler N
    type
    Author
  8. name
    Delwail V
    type
    Author
  9. name
    Press O
    type
    Author
  10. name
    Salles G
    type
    Author
  11. name
    Gribben J
    type
    Author
  12. name
    Lennard A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Sehn LH
    type
    Author
  2. name
    Chua N
    type
    Author
  3. name
    Mayer J
    type
    Author
  4. name
    Dueck G
    type
    Author
  5. name
    Trněný M
    type
    Author
  6. name
    Bouabdallah K
    type
    Author
  7. name
    Fowler N
    type
    Author
  8. name
    Delwail V
    type
    Author
  9. name
    Press O
    type
    Author
  10. name
    Salles G
    type
    Author
  11. name
    Gribben J
    type
    Author
  12. name
    Lennard A
    type
    Author
bibliography ids
  1. nci-bib-95aed620a7d8cbc41d020364
book metadata
content sha256
158ece89504c200efcb17c7c61371cac5e755b4d29ade4279d48f1a92c57ec69
document type
citation
dois
  1. 10.1016/S1470-2045(16)30097-3
electronic publication date
display
2016 Jun 23
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:27345636
immutable id
pubmed:27345636@158ece89504c200efcb17c7c61371cac5e755b4d29ade4279d48f1a92c57ec69
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
8
name
The Lancet. Oncology
nlm unique id
100957246
pages
1081-1093
volume
17
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Aug;17(8):1023-1025. doi: 10.1016/S1470-2045(16)30157-7.
    note
    Source null
    related pmid
    27345637
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2016 Aug;13(8):466. doi: 10.1038/nrclinonc.2016.112.
    note
    Source null
    related pmid
    27402577
    relationship
    Comment in
outcomes validated
false
pmid
27345636
provenance
batch id
fe5a46c92522c34737e8
provider
NCBI PubMed ESummary
record sha256
f9c09916503b540419fd7e0a123034a081debf753c809f0264f617cd0874efa0
response sha256
2c7bacd02d2ece3813daf1a0f92260c22884bd9268942fcca2088ab229bfb4d1
retrieved at
2026-09-09T23:47:17.939307+00:00
publication date
display
2016 Aug
precision
month
year
2016
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/27345636/
title
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.

Preserved source evidence · Independent clinical review pending · Not medical advice